ReviewPharmaceutics2025
An Overview of the Bioactivity of Spontaneous Medicinal Plants Suitable for the Improvement of Lung Cancer Therapies.
Review in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Article
- Multi-Target Antitumor Effects of Natural Products and Approved Drug Repurposing in Non-Small Cell Lung Cancer: Advances in Mechanisms, Combination Regimens, Delivery System Optimization, and Clinical Challenges.International journal of molecular sciences · 2026Review
- Biological and Phytochemical Profile of Volatile Oils from Romanian Mountain Flora.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Antimicrobial potential of different bee product-loaded carboxymethyl chitosan nanoparticles against multidrug-resistant clinical pathogens: a comparative in vitro study.BMC biotechnology · 2026Article
- Protein Fraction and Derived Peptides fromInternational journal of molecular sciences · 2026Article
- (-)-Epi-Osmundalactone-Rich Fraction fromPlants (Basel, Switzerland) · 2026Article
- Effects of Thymoquinone on Cell Proliferation, Oxidative Damage, and Toll-like Signaling Pathway Genes in H1650 Lung Adenocarcinoma Cell Line.Medicina (Kaunas, Lithuania) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Lung cancer is the second cause of death in the world, being the most common type of cancer. Conventional therapies are not always recommended due to the particularities of patients. Thus, there is a need to develop new anticancer therapeutic agents. Medicinal plants constitute a source of bioactive compounds with therapeutic potential in lung cancer. The purpose of our narrative review is to evaluate and summarize the main studies on the cytotoxic effects of ten medicinal plants and their extracts, volatile oils, and bioactive compounds. We have also included studies that reported protective effects of these natural products against chemotherapy-induced toxicity. Studies were identified by assessing five databases using specific keywords. The investigated natural products possess cytotoxic effects on lung cancer cell cultures. Several mechanisms of action have been proposed including cell death by apoptosis, necrosis or autophagy, cell cycle arrest, the modulation of signaling pathways (PI3K/Akt and MAPK), the inhibition of migration, invasion and metastasis, antiangiogenesis, and targeting inflammation. Different bioactive compounds exhibit protective effects against chemotherapy-induced toxicity. Studies have shown promising results. To develop new therapeutic agents useful in treating lung cancer, the plants included in this review should be more deeply investigated to reveal their molecular mechanisms of action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.